FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045125412> ?p ?o ?g. }

• W2045125412 abstract "Type II diabetes mellitus is a major public health problem afflicting in excess of 250 million individuals worldwide. The presence of this condition in patients with coronary artery disease more than doubles their risk for cardiovascular events. Among the most critical factors are the attendant development of endothelial dysfunction and insulin resistance, which contribute to impaired glycaemic control and acceleration of atherosclerosis. Contemporary therapies have important limitations and safety concerns, as treatment with agents in extensive clinical use, including β-adrenergic receptor blocking agents, thiazide diuretics, and calcium channel antagonists, is associated with increased rates of newly diagnosed diabetes as a result of pro-diabetic effects.These limitations have prompted a search for alternative modalities of drug action. In the current issue of The Journal of Physiology, Fu and colleagues (2013) explored whether ranolazine can improve blood flow and distribution of insulin through α-adrenergic receptor-mediated vasodilatation. Ranolazine is a weak competitive antagonist of α-adrenergic receptors (Allely et al. 1993) and in the conscious dog this antagonism is unmasked by activation of the autonomic nervous system (Zhao et al. 2011).Fu and colleagues (2013) reported that in the therapeutic range of doses ranolazine recruited muscle microvasculature, resulting in a significant >2-fold increase in skeletal muscle blood flow and volume and a substantial enhancement of insulin-mediated whole-body disposal in the range of 30%. In addition, ranolazine improved delivery of insulin into skeletal muscle. Ranolazine increased endothelial nitric oxide synthase (eNOS) phosphorylation and cyclic adenosine monophosphate (cAMP) production without affecting endothelial insulin uptake. Isolated phenylephrine pre-constricted arterial rings were relaxed in the presence of ranolazine, indicating an α-adrenergic receptor-mediated effect. This observation is consistent with evidence obtained in vivo in which the vasoconstrictor effect of intracoronary phenylephrine was abolished by ranolazine (Nieminen et al. 2011) and the vasopressor response to methoxamine was blunted by ranolazine in a dose-dependent manner (Wang et al. 2008). Fu and colleagues (2013) also found that the vasodilatory effects on the pre-capillary arterioles occurred via actions on both the endothelium and smooth muscle cells.Overall, their observations indicate that at therapeutic concentrations ranolazine acutely recruits skeletal muscle microvasculature, increasing microvascular exchange surface area and perfusion. This effect, in combination with the drug's α-adrenergically mediated vasodilatation of pre-capillary arterioles, improves insulin delivery to skeletal muscle and glucose use.This intriguing study by Fu and coworkers (2013) raises important questions relevant to potential clinical applications. As the present studies were performed on an acute basis in normal rats, it remains to be determined whether microvascular recruitment persists following chronic administration in a diabetic animal model. Also, is there evidence that this action of ranolazine on muscle microvasculature operates in patients with various degrees of insulin resistance and early and late stage type 2 diabetes?Clinical trials have demonstrated that ranolazine significantly improves glycaemic control as suggested by reduced levels of glycated haemoglobin (HbA1c) in diabetic as well as non-diabetic subjects (Timmis et al. 2006; Morrow et al. 2009; Chisholm et al. 2010; Kosiborod et al. 2013). Use of ranolazine is also attractive in light of the excellent safety profile shown in the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in NonST-Elevation Acute Coronary Syndromes Thrombolysis in Myocardial Infarction 36) trial, which enrolled 6560 patients with cardiovascular disease, 2028 (31%) of whom had pre-existing diabetes (Morrow et al. 2009). However, the mechanisms whereby ranolazine reduces HbA1c remain unknown.The clinical implications of this study are multifold and significant. Essentially, the authors have identified mechanisms that may underlie ranolazine's unique salutary effects, which can potentially improve the cardiovascular health of diabetic patients while reducing myocardial ischaemic events and risk for atrial and ventricular arrhythmias. Although considerable further work will be required to assess fully the clinical applicability of Fu and coworkers’ novel findings (2013), available clinical evidence suggests that the basic concept presented in the current study is promising and worthy of vigorous pursuit." @default.
• W2045125412 created "2016-06-24" @default.
• W2045125412 creator A5021644068 @default.
• W2045125412 date "2013-10-14" @default.
• W2045125412 modified "2023-09-26" @default.
• W2045125412 title "Ranolazine's sweet side - improvement of glycaemic control by the novel mechanism of skeletal muscle microvascular recruitment" @default.
• W2045125412 cites W126353551 @default.
• W2045125412 cites W1972348450 @default.
• W2045125412 cites W2008823669 @default.
• W2045125412 cites W2026161823 @default.
• W2045125412 cites W2065043322 @default.
• W2045125412 cites W2079337202 @default.
• W2045125412 cites W2130710856 @default.
• W2045125412 cites W2169525160 @default.
• W2045125412 doi "https://doi.org/10.1113/jphysiol.2013.260687" @default.
• W2045125412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3810802" @default.
• W2045125412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24130322" @default.
• W2045125412 hasPublicationYear "2013" @default.
• W2045125412 type Work @default.
• W2045125412 sameAs 2045125412 @default.
• W2045125412 citedByCount "0" @default.
• W2045125412 crossrefType "journal-article" @default.
• W2045125412 hasAuthorship W2045125412A5021644068 @default.
• W2045125412 hasBestOaLocation W20451254122 @default.
• W2045125412 hasConcept C120770815 @default.
• W2045125412 hasConcept C126322002 @default.
• W2045125412 hasConcept C134018914 @default.
• W2045125412 hasConcept C2777391703 @default.
• W2045125412 hasConcept C2779177932 @default.
• W2045125412 hasConcept C2779306644 @default.
• W2045125412 hasConcept C2780972559 @default.
• W2045125412 hasConcept C555293320 @default.
• W2045125412 hasConcept C71924100 @default.
• W2045125412 hasConcept C98274493 @default.
• W2045125412 hasConceptScore W2045125412C120770815 @default.
• W2045125412 hasConceptScore W2045125412C126322002 @default.
• W2045125412 hasConceptScore W2045125412C134018914 @default.
• W2045125412 hasConceptScore W2045125412C2777391703 @default.
• W2045125412 hasConceptScore W2045125412C2779177932 @default.
• W2045125412 hasConceptScore W2045125412C2779306644 @default.
• W2045125412 hasConceptScore W2045125412C2780972559 @default.
• W2045125412 hasConceptScore W2045125412C555293320 @default.
• W2045125412 hasConceptScore W2045125412C71924100 @default.
• W2045125412 hasConceptScore W2045125412C98274493 @default.
• W2045125412 hasLocation W20451254121 @default.
• W2045125412 hasLocation W20451254122 @default.
• W2045125412 hasLocation W20451254123 @default.
• W2045125412 hasOpenAccess W2045125412 @default.
• W2045125412 hasPrimaryLocation W20451254121 @default.
• W2045125412 hasRelatedWork W1510697985 @default.
• W2045125412 hasRelatedWork W1585544681 @default.
• W2045125412 hasRelatedWork W174147895 @default.
• W2045125412 hasRelatedWork W1972348450 @default.
• W2045125412 hasRelatedWork W2021672176 @default.
• W2045125412 hasRelatedWork W2072140142 @default.
• W2045125412 hasRelatedWork W2085609603 @default.
• W2045125412 hasRelatedWork W2097427193 @default.
• W2045125412 hasRelatedWork W2104357603 @default.
• W2045125412 hasRelatedWork W2181472722 @default.
• W2045125412 hasRelatedWork W2248194776 @default.
• W2045125412 hasRelatedWork W2420371208 @default.
• W2045125412 hasRelatedWork W2592214652 @default.
• W2045125412 hasRelatedWork W2808761018 @default.
• W2045125412 hasRelatedWork W2995407177 @default.
• W2045125412 hasRelatedWork W3022230909 @default.
• W2045125412 hasRelatedWork W3080645788 @default.
• W2045125412 hasRelatedWork W3195190493 @default.
• W2045125412 hasRelatedWork W4226065332 @default.
• W2045125412 hasRelatedWork W75020429 @default.
• W2045125412 isParatext "false" @default.
• W2045125412 isRetracted "false" @default.
• W2045125412 magId "2045125412" @default.
• W2045125412 workType "article" @default.